- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05712681
Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy Volunteers
January 25, 2023 updated by: Onconic Therapeutics Inc.
A Randomized, Open-label, Crossover Phase 1 Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy Volunteers
To Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral single dose of JP-1366 tablet in Healthy volunteers
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Asan Medical Central
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- A healthy adult aged between 19 and 45 years old
- BMI between 18.0kg/m2 and 27.0kg/m2 at the time of screening
Exclusion Criteria:
- The subject who has clinically significant disease with liver, endocrine system, immune system, nervous system, kidney, cardiovascular disease, mental disorder, the blood of tumor disease, respiratory system or with history of the disease.
- The subject who has a history of gastrointestinal disorders(e.g., gastroesophageal reflux disease, gastrospasm, gastritis, gastrointestinal ulcers, Crohn's disease, etc.) or history of gastrointestinal surgery
- The subject who has an allergic disease(excluding mild allergic rhinitis that does not require administration) or has a history of clinically significant hypersensitivity or adverse reactions to clinical trial drugs or drugs containing the same or other drugs (aspirin, NSAIDs, antibiotics, etc.).
- The subject who has other clinically significant diseases or history
- The subject who has a history of drug abuse
- The subject who cannot withstand the insertion and maintenance of pH catheters
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Sequence 1
T → Washout period(7-14days) → R
|
T : JP-1366 20mg tablet after the meal
R : JP-1366 20mg tablet under fasting condition
|
EXPERIMENTAL: Sequence 2
R → Washout period(7-14days) → T
|
T : JP-1366 20mg tablet after the meal
R : JP-1366 20mg tablet under fasting condition
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax of JP-1366
Time Frame: Pre-dose(0 hour) and up to 34 hours in each period
|
Pre-dose(0 hour) and up to 34 hours in each period
|
AUClast of JP-1366
Time Frame: Pre-dose(0 hour) and up to 34 hours in each period
|
Pre-dose(0 hour) and up to 34 hours in each period
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Gastric pH
Time Frame: Pre-dose(0 hour) up to 24 hours after Investigational product administration
|
Pre-dose(0 hour) up to 24 hours after Investigational product administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
February 1, 2023
Primary Completion (ANTICIPATED)
April 1, 2023
Study Completion (ANTICIPATED)
May 1, 2023
Study Registration Dates
First Submitted
January 13, 2023
First Submitted That Met QC Criteria
January 25, 2023
First Posted (ACTUAL)
February 3, 2023
Study Record Updates
Last Update Posted (ACTUAL)
February 3, 2023
Last Update Submitted That Met QC Criteria
January 25, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- JP-1366-105
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on JP-1366 20mg tablet
-
Onconic Therapeutics Inc.CompletedHealthyKorea, Republic of
-
Jeil Pharmaceutical Co., Ltd.Completed
-
Onconic Therapeutics Inc.RecruitingErosive EsophagitisKorea, Republic of
-
Onconic Therapeutics Inc.Completed
-
Onconic Therapeutics Inc.Not yet recruiting
-
Onconic Therapeutics Inc.CompletedAnti-Ulcer AgentsKorea, Republic of
-
Onconic Therapeutics Inc.CompletedHelicobacter Pylori Associated Gastrointestinal DiseaseKorea, Republic of
-
St. Joseph's Healthcare HamiltonPfizer; McMaster UniversityUnknownSleep | Menopause | Depression, Anxiety
-
Sarfez Pharmaceuticals, Inc.CompletedChronic Kidney Diseases | Congestive Heart FailureIndia
-
Yuhan CorporationLinical KoreaTerminatedA Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic SyndromeMetabolic SyndromeKorea, Republic of